Oral Cannabis Extract for Secondary Prevention of Chemotherapy-Induced Nausea and Vomiting: Final Results of a Randomized, Placebo-Controlled, Phase II/III Trial From March 2022 to December 2023, a ...
Analysts downgraded uniQure N.V. after the U.S. Food and Drug Administration signalled it would require a sham surgery-controlled Phase 3 trial for the company’s Huntington’s disease therapy, dimming ...
一部の結果でアクセス不可の可能性があるため、非表示になっています。
アクセス不可の結果を表示する